Shionogi reaches primary endpoint for ensitrelvir
Positive results in COVID-19 therapy phase 3 trials show effectiveness against five symptoms
Read More
Tag: Shionogi
Shionogi and NEC collaborate on hepatitis B vaccine
High unmet need in the area of hepatitis B therapies will see companies share responsibilities to develop the vaccine
Read More
NICE backs Sandoz’ Rizmoic
NHS funding has been approved for the drug’s use as a treatment for opioid-induced constipation
Read More
Shionogi launches novel antibiotic Fetcroja in the UK
The drug is indicated for use as a treatment of infections caused by aerobic Gram-negative bacteria
Read More
EC approves Shionogi’s new antibiotic Fetcroja
Fetcroja is the first treatment to provide coverage against all Gram-negative pathogens considered of critical priority
Read More
Seven medicines leap closer to EU approval
The European Medicines Agency’s human medicines committee (CHMP) has put forward seven medicines for approval in the region.
Read More
US approves first-in-class flu drug
The US Food and Drug Administration has approved Roche/Shionogi & Co’s Xofluza for the treatment of acute uncomplicated flu, opening the door to the first new antiviral with a novel mechanism of action in nearly 20 years.
Read More
Priority review for Genentech’s flu drug
The US Food and Drug Administration will undertake a priority review of Genentech’s experimental flu drug baloxavir marboxil in people aged 12 years and older.
Read More
Shire’s Intuniv hits targets in adult ADHD trial
Data from a Phase III study evaluating Shire’s Intuniv in Japan in adults with attention deficit hyperactivity disorder indicate that the drug could improve symptoms of the condition in this patient group.
Read More
ViiV’s long-acting two-drug HIV regimen hits targets
A long-acting, two-drug HIV regimen being co-developed by ViiV Healthcare and Janssen Sciences Ireland UC has shown comparable viral suppression rates to a three-drug regimen in a Phase II trial, indicating its potential to reduce the dosing burden for patients and thus improve treatment adherence.
Read More
ViiV kicks off PhIII trials of HIV regimen
ViiV Healthcare has kicked off two late stage studies assessing a potential new regimen for the treatment of HIV-1 infection.
Read More
- Vandria reports positive phase 1 data for Alzheimer’s drug candidate
- HSE approves new treatment for hidradenitis suppurativa and axial spondyloarthritis
- MSD to acquire Cidara after positive phase 2b trial results
- eXmoor Pharma and Royal Free London link to strengthen UK gene therapy
- Alzheimer’s prevention charity pioneers research on nutrition biomarkers to detect risk
